November 14, 2023Journal of Cardiovascular PharmacologyOpen Access

HR 0.78 (95% CI 0.71-0.86, P < 0.0001) for the composite of worsening HF or cardiovascular death.

View Full Paper

Ask AI

Bookmark

Why the study?

Studies examining the benefits of SGLT2 inhibitors exclusively in nondiabetic patients across various heart failure outcomes are limited.

Do SGLT2 inhibitors reduce worsening heart failure or cardiovascular death in nondiabetic patients with heart failure?

Population

10,638 nondiabetic patients across 4 randomized controlled trials

Comparison

SGLT2i vs placebo

Design

Systematic review and meta-analysis of randomized controlled trials

Authors

SKSharath Kommu

Discussion

Member takes

Overview

Supports SGLT2i use in nondiabetic HF; extends RCT evidence to this subgroup.

Structured PICO

Do SGLT2 inhibitors reduce worsening heart failure or cardiovascular death in nondiabetic patients with heart failure?

Population

10,638 nondiabetic patients with heart failure pooled from 4 randomized controlled trials

Intervention

SGLT2 inhibitors as a class

Comparator

Placebo

Outcome

Composite of worsening HF (hospitalization for HF or urgent visit for HF) or cardiovascular deathcomposite

SGLT2 inhibitors significantly improve heart failure outcomes, including reducing hospitalizations for HF, in patients with heart failure who do not have diabetes mellitus.

Cite This Study

Sharath Kommu (2023) studied this question.

synapsesocial.com/papers/6a783adcd2fa2470761f5cd6 https://doi.org/10.1097/fjc.0000000000001511

View Full Paper

Ask AI

Bookmark

November 14, 2023Journal of Cardiovascular PharmacologyOpen Access

HR 0.78 (95% CI 0.71-0.86, P < 0.0001) for the composite of worsening HF or cardiovascular death.

View Full Paper

Ask AI

Bookmark

Why the study?

Studies examining the benefits of SGLT2 inhibitors exclusively in nondiabetic patients across various heart failure outcomes are limited.

Do SGLT2 inhibitors reduce worsening heart failure or cardiovascular death in nondiabetic patients with heart failure?

Population

10,638 nondiabetic patients across 4 randomized controlled trials

Comparison

SGLT2i vs placebo

Design

Systematic review and meta-analysis of randomized controlled trials

Authors

SKSharath Kommu

Discussion

Member takes

Overview

Supports SGLT2i use in nondiabetic HF; extends RCT evidence to this subgroup.

Structured PICO

Do SGLT2 inhibitors reduce worsening heart failure or cardiovascular death in nondiabetic patients with heart failure?

Population

10,638 nondiabetic patients with heart failure pooled from 4 randomized controlled trials

Intervention

SGLT2 inhibitors as a class

Comparator

Placebo

Outcome

Composite of worsening HF (hospitalization for HF or urgent visit for HF) or cardiovascular deathcomposite

SGLT2 inhibitors significantly improve heart failure outcomes, including reducing hospitalizations for HF, in patients with heart failure who do not have diabetes mellitus.

Cite This Study

Sharath Kommu (2023) studied this question.

synapsesocial.com/papers/6a783adcd2fa2470761f5cd6 https://doi.org/10.1097/fjc.0000000000001511

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark